目的 探討金胃泰膠囊聯(lián)合柳氮磺吡啶治療慢性潰瘍性結(jié)腸炎的臨床療效。方法 選取2018年9月-2020年9月在天津醫(yī)科大學(xué)第二醫(yī)院住院治療的96例潰瘍性結(jié)腸炎患者，根據(jù)隨機(jī)數(shù)字法分為對(duì)照組和治療組，每組各48例。對(duì)照組患者口服柳氮磺吡啶腸溶片，4片/次，3次/d。治療組患者在對(duì)照組的基礎(chǔ)上口服金胃泰膠囊，3粒/次，3次/d。兩組患者連續(xù)治療2周。觀察兩組的臨床療效，比較兩組臨床癥狀緩解時(shí)間和血清炎性因子水平。結(jié)果 治療后，治療組患者總有效率為97.92%，顯著高于對(duì)照組的85.42%（P<0.05）。治療后，治療組患者腹瀉緩解時(shí)間、腹痛緩解時(shí)間、膿血便緩解時(shí)間、充血水腫緩解時(shí)間、黏膜潰瘍緩解時(shí)間均顯著短于對(duì)照組（P<0.05）。治療后，兩組患者白細(xì)胞介素6（IL-6）、腫瘤壞死因子α（TNF-α）、C反應(yīng)蛋白（CRP）水平均顯著降低，白細(xì)胞介素2（IL-2）顯著升高（P<0.05）；治療后，治療組患者血清炎性因子水平改善優(yōu)于對(duì)照組（P<0.05）。結(jié)論 金胃泰膠囊聯(lián)合柳氮磺吡啶治療潰瘍性結(jié)腸炎具有顯著療效，可有效緩解患者臨床癥狀，降低炎性反應(yīng)，值得在臨床上借鑒與推廣使用。

Objective To investigate the therapeutic effect of Jinweitai Capsules combined with sulfasalazine in treatment of chronic ulcerative colitis. Methods A total of 96 patients with ulcerative colitis hospitalized in the Second Hospital of Tianjin Medical University from September 2018 to September 2020 were selected and divided into control group and treatment group according to random number method, with 48 cases in each group. Patients in the control group were po administered with Sulfasalazine Enteric-coated Tablets, 4 tablets/time, three times daily. Patients in the treatment group were po administered with Jinweitai Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in both groups were treated for 2 weeks. The clinical efficacy of the two groups were observed, and the remission time of clinical symptoms and the level of serum inflammatory factors were compared between the two groups. Results After treatment, the total effective rate in treatment group was 97.92%, significantly higher than 85.42% in control group (P<0.05). After treatment, the relief time of diarrhea, abdominal pain, pus, blood and stool, hyperemia and edema and mucosal ulcer in the treatment group was significantly shorter than that in the control group (P<0.05). After treatment, the levels of interleukin 6 (IL-6), tumor necrosis factor α (TNF-α) and C-reactive protein (CRP) in two groups were significantly decreased compared with before treatment, but interleukin 2 (IL-2) was significantly increased (P<0.05). After treatment, the improvement of serum inflammatory factors in treatment group was better than that in control group (P<0.05). Conclusion Jinweitai Capsules combined with sulfasalazine has significant curative effect in treatment of chronic ulcerative colitis, and can effectively relieve the clinical symptoms of patients and reduce the inflammatory reaction, which is worthy of clinical reference and promotion.

R975

天津市衛(wèi)生計(jì)生委、天津市中醫(yī)藥管理局中醫(yī)、中西醫(yī)結(jié)合科研項(xiàng)目（2017095）